AbbVie is licensing rights to a drug from Gubra that has encouraging early clinical data in obesity. The once-weekly injectable peptide is a dual agonist of the amylin and calcitonin receptors, both of which play key roles in metabolism.
The post AbbVie Enters Obesity Field, Paying $350M for Amylin Receptor Agonist Already in the Clinic appeared first on MedCity News.
